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METAANALYSIS OF REAL-WORLD OUTCOMES OF
INTRAVITREAL RANIBIZUMAB FOR THE
TREATMENT OF NEOVASCULAR AGE-RELATED
MACULAR DEGENERATION
LEAH N. KIM,* HEMAL MEHTA, MA, FRCOPHTH,*† DANIEL BARTHELMES, PHD, FEBO,*‡
VUONG NGUYEN, PHD,* MARK C. GILLIES, PHD, FRANZCO*
Purpose: To report the efﬁcacy and safety of intravitreal ranibizumab for neovascular
age-related macular degeneration (nAMD) in real-world practice.
Methods: Metaanalysis of 26,360 patients from 42 real-world observational studies
reporting outcomes of intravitreal ranibizumab for nAMD published between 2007 and
2015. Baseline demographics, lesion type, and visual acuity (VA) were recorded. The
weighted mean was calculated for change in VA and frequency of injections and visits
during year 1, year 2, and $3 years. Local and systemic adverse events were recorded.
Results: The mean change in VA for patients receiving a treat-and-extend regimen was
+8.8 (95% conﬁdence interval [CI]: 5.8 to 11.8), +6.7 (95% CI: 3.2 to 10.1), and +5.4 (95%
CI: 24.1 to 14.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letters at 1 year (n =
1,539), 2 years (n = 2,521), and $3 years (n = 1,298), in comparison with +3.5 (95% CI: 2.0
to 5.0), +1.3 (95% CI: 21.6 to 4.2), and 21.9 (95% CI: 29.8 to 6.0) ETDRS letters for pro re
nata at 1 year (n = 20,247), 2 years (n = 14,408), and $3 years (n = 11,714). Treat-and-
extend patients received on average more injections (6.9 vs. 4.7) but had fewer visits (7.6
vs. 9.2) in the ﬁrst year. Baseline characteristics were similar between the regimens. The
reported rate of endophthalmitis was 17 of 66,176 intravitreal injections (0.026%).
Conclusion: Intravitreal ranibizumab for nAMD prevents severe visual loss in real-world
practice. Patients can achieve visual gain from baseline, but the extent to which these are
maintained in the long term may depend on the frequency of injections.
RETINA 36:1418–1431, 2016
Age-related macular degeneration is the leadingcause of irreversible blindness in the developed
world1 and accounts for 5% of all blindness world-
wide.2 Humanized antibodies that inhibit vascular
endothelial growth factor have been widely used clin-
ically over the past decade after several randomized
controlled trials demonstrated their beneﬁt in improv-
ing visual outcomes in patients with neovascular age-
related macular degeneration (nAMD).3 However,
there are several different treatment regimens for
nAMD, including ﬁxed dosing, pro re nata (PRN),
and treat-and-extend.
Continuous monthly intravitreal ranibizumab ther-
apy for nAMD was shown to be efﬁcacious in the
landmark MARINA4 and ANCHOR5 clinical trials.
However, In real-world practice, many patients treated
for nAMD do not meet the stringent inclusion criteria
of these clinical trials. Also, monthly intravitreal in-
jections pose a signiﬁcant treatment burden for
patients, carers, and healthcare providers. Therefore,
discontinuous treatment regimens have become popu-
lar as they are more practical in the real-world setting.
Discontinuous regimens include PRN, where patients
are treated only when lesions are active, or “treat and
extend,” in which the interval between treatments is
increased when the disease is stable with the aim of
injecting just before the lesion is about to reactivate.
Because of constraints in healthcare costs around the
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world, different restrictions are placed on clinicians
regarding frequency of treatments and patient visits.
The aim of this metaanalysis was to assess whether
the impressive outcomes demonstrated from Phase 3
clinical trials translate to real-world clinical practice.5
We paid particular attention to how visual acuity (VA)
outcomes vary according to different treatment regi-
mens across the world.
Methods
Search Strategy
A systematic search of the literature was conducted
on May 1, 2015, using Medline, Embase, and Cochrane
library databases. The ﬁelds searched by a multipurpose
(.mp) search in Ovid databases generally looked in the
Title, Original Title, Abstract, Subject Heading, Name
of Substance, and Registry Word ﬁelds. The following
search terms were used: age related macular degener-
ation.mp or macular degeneration; AMD.mp; neovas-
cular.mp; wet.mp or wet macular degeneration;
vascular endothelial growth factors; visual acuity or
visual outcomes; vision; ocular; blindness; registry.mp
or registries; database.mp; long-term studies.mp;
observation studies; phase IV study. Further references
were identiﬁed by manually searching included articles
and consulting experts in the ﬁeld.
Study Selection
Real-world studies of intravitreal ranibizumab ther-
apy for nAMD published before the search date were
included. Where possible, patients with at least one year
follow-up were included. Randomized clinical trial
results were excluded. Because there were no language
exclusions in this metaanalysis, article abstracts were
translated if required during the selection process and if
included the full article was translated. The studies were
grouped according to the region in the world where they
were conducted, and then arranged with the most recent
publication ﬁrst.
Quality of Evidence
The selected studies are observational in nature and
therefore provide low to moderate overall quality of
evidence based on the Grading of Recommendations
Assessment, Development and Evaluation classiﬁcation.6
Data Extraction and Synthesis
The following data were extracted from each report:
1. Study design
2. Number of patients
3. Mean age of patients
4. Sex ratio
5. Baseline choroidal neovascularization (CNV)
lesion type—predominantly classic, minimally
classic (MC), occult, and other
6. Visual acuity at baseline, 1 year, 2 years, and $3
years after commencing anti–vascular endothelial
growth factor treatment
7. Mean number of intravitreal injections administered
per year
8. Total number of intravitreal injections administered
9. Mean number of visits per year
10. Treatment regimen and dosage
11. Total number of adverse events, speciﬁcally
related to the ranibizumab therapy if speciﬁed
12. Number of cases of endophthalmitis, cerebrovas-
cular accidents, and acute coronary syndromes
13. Number of deaths
The total number of patients enrolled across all
studies was calculated as most studies reported the
number of patients, rather than the number of eyes
included. If a study only reported the number of eyes,
it was assumed that one eye per patient was included.
Studies were scrutinized to ensure that the patient
population was analyzed once only where multiple
studies on the same population were performed.
Visual acuity scores were converted to Early
Treatment Diabetic Retinopathy Study (ETDRS) let-
ters for consistency, and approximate Snellen ratios
were also noted.
Statistical Analysis
The weighted mean values for baseline age, sex ratio,
CNV characteristics, VA, for yearly VA changes, the
number of intravitreal injections, and patient visits per
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year were calculated across all studies. This was
accomplished by weighting each study according to the
proportion of patients it contributed to the metaanalysis.
To account for heterogeneity in outcome measures
between studies, we also ﬁt random-effects models to
produce estimates for baseline age and VA, yearly VA
changes, and the number of intravitreal injections and
patient visits per year. Heterogeneity between studies was
measured using the I2 statistic to quantify the amount of
inconsistency (i.e., heterogeneity), where I2 values of
25%, 50%, and 75% indicate low, moderate, and sub-
stantial heterogeneity, respectively.7 Mixed-effects mod-
els were also conducted using study region and treatment
regimen as moderators to test as potential sources of
heterogeneity and to provide estimates for yearly VA
change and injections received by region and treatment
regimen. The proportional reduction in variance was cal-
culated to estimate the amount of heterogeneity that can
be accounted for by the moderators, which can be thought
of as a pseudo R2 statistic.8 When studies did not report
the standard deviation, these values were imputed via
multiple imputations and model results pooled.9,10
The ratio of injections to visits was calculated when
these data were available.
When combined values were reported for MC and
occult lesions, they were analyzed as part of the occult
category. Otherwise, data on CNV characteristics that
could not be separated into clinically relevant lesion
types were excluded from this aspect of the analysis.
When the total number of intravitreal injections
administered in a study was unavailable, it was
calculated by multiplying the mean number of in-
jections by the total number of patients in the study.
Analyses were conducted using R version 3.2.3 and
the mice (for multiple imputations) and metafor (for
random- and mixed-effects models) packages.8,11,12
Results
Included Studies
The literature search returned a total of 613 articles.
Based on our inclusion and exclusion criteria, 42
articles published between 2007 and May 2015 were
included. There were a total of 45,381 patients with
nAMD across all the studies included. However,
taking into account multiple studies that were based
on the same patient population, 26,360 different
patients were included.
Summary Tables
The patient demographics in these studies are summa-
rized in Table 1, with the corresponding VA data and
treatment regimens listed in Table 2. The safety outcomes
of each study are presented in Table 3. Table 4 summa-
rizes the weighted outcome means and overall outcomes
measures as estimated by random-effects models, regional
and treatment regimen outcome measures as estimated by
mixed-effects models, and an assessment of heterogeneity.
Baseline Characteristics
The mean age of patients across all studies was 78.8
years (95% conﬁdence interval [CI]: 78.0 to 79.5) and
63.3% were female. There was a wide range in the
mean baseline VA across studies (36.5–75.0 ETDRS
letters; 6/60 to 6/9.5 Snellen approximate). The mean
baseline VA for the pooled data was 53.6 ETDRS
letters (6/24 Snellen approximate).
Patients treated under PRN regimens had a mean age
of 78.5 years and mean baseline VA of 53.0 ETDRS
letters (6/24 Snellen approximate). For patients under
treat-and-extend regimens, their mean age was 79.0 years
and their mean baseline VA was 52.0 ETDRS letters (6/
24 Snellen approximate). Females accounted for 63.4%
and 62.2% of patients in PRN and treat-and-extend
regimens, respectively. The mean baseline VA for studies
from Europe, United Kingdom, and Australia were 56.0,
53.6, 46.6, and 57.5 ETDRS letters, respectively, (6/24,
6/24, 6/38, and 6/19 Snellen approximates, respectively).
Of the 9,350 patients with data available on their
CNV lesion, the majority had an occult lesion (50.2%),
followed by predominantly classic (21.1%), unclassi-
ﬁed (17.5%), MC (8.1%), and others including retinal
angiomatous proliferation (3.1%). This distribution was
similar for both PRN and treat-and-extend regimens.
Holz et al13 also reported that 11.7% (n = 199) of their
patients had both occult and classic lesions. Heimes
et al14 and Pushpoth et al15 reported the combined
number of patients with either predominantly or MC
lesions. These two values could not be separated and
were therefore excluded from the analysis of lesion
type. Pushpoth et al,15 Katz et al,16 and Abedi et al17
reported the combined number of patients with MC or
occult lesions, and these were included into the occult
category for analysis.
For comparison, the baseline characteristics of the
MARINA and ANCHOR clinical trials using 0.5-mg
ranibizumab were mean baseline best-corrected VA of
53.7 and 47.1 ETDRS letters (6/24 and 6/38 Snellen
approximates), mean age of 77.0 and 76.0 years, and
the mean percentage of females 63.3% and 46.4%,
respectively.
Visual Acuity Outcomes
Overall, there was a mean change of +5.0 (95% CI:
3.4 to 6.6), +3.4 (95% CI: 0.9 to 5.8), and +1.1 (95%
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Table 1. Demographic Information of the Patients in the Included Studies
Article
Patients
(n) Mean Age (Years) Female (%)
Baseline CNV (%)
Study TypePC MC Occult Other
International
Holz et al13 2,227 76.9 60.6 27.7 — 40.6 0.5 Retrospective
Germany 420 76.7 59.8 — — — — —
France 398 77.5 60.6 — — — — —
United Kingdom 410 77.7 60.2 — — — — —
Italy 365 75.2 58.1 — — — — —
Netherlands 350 77.2 62.9 — — — — —
Canada 188 79.8 60.6 — — — — —
Ireland 49 72.7 73.5 — — — — —
Venezuela 47 73.1 59.6 — — — — —
Silva et al21 210 75.7 56.8 — — — — Phase 4 extension study
Continental Europe
Souied et al22 881 79.0 68.0 27.8 11.0 61.3 — Retrospective
van Asten et al23 231 77.9 58.9 17.7 16.9 61.9 3.5 Prospective
Frennesson and Nilsson24 268 78.9 66.8 19.2 11.2 43.9 25.6 Retrospective
Mantel et al25 104* 79.5 63.5 24.4 10.4 45.2 20.0 Prospective
Menghini et al26 194 79.3 63.2 17.2 12.3 70.5 — Retrospective
Wolf and Kampik27 1,729 77.8 63.2 24.4 7.8 41.3 — Prospective
Cohen et al28 551 78.2 63.2 33.3 12.0 54.7 — Retrospective
Falk et al29 855 77.3 62.8 — — — Retrospective
Finger et al30 3,470 #65 (5.6%) 66–80 (51.3%)
.80 (42.3%)
64.6 24.5 11.6 63.9 — —
Holz et al31 4,444 — — — — — — Retrospective
Germany 3,470 77.6 64.6 — — — — —
Netherlands 243 77.9 59.3 — — — — —
Belgium 260 78.7 62.1 — — — — —
Sweden 471 78.1 66.0 — — — — —
Rakic et al32 267 78.5 62.4 18.0 8.2 60.4 34.2 Prospective
Biarnés et al33 67 77.8 80.0 13.0 11.0 34.0 — Retrospective
Heimes et al14 145 77.1 70.3 15.1 84.8 — Retrospective
Hjelmqvist et al19 370 77.7 66.8 — — — — Prospective and retrospective
Oubraham et al34 — — — — — — — Retrospective
PRN 52 79.1 53.0 26.9 — 63.0 9.6
Treat and extend 38 79.1 65.0 15.8 — 84.0 —
Querques et al35 79 77.17 58.3 8.3 15.6 76.0 Retrospective
Cohen et al36 122 78.3 70.0 25.0 — 75.0 — —
Rothenbuehler et al37 138 76.5 64.0 31.0 4.0 65.0 — Prospective
(continued on next page)
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Table 1. (Continued )
Article
Patients
(n) Mean Age (Years) Female (%)
Baseline CNV (%)
Study TypePC MC Occult Other
United Kingdom
Writing Committee for the U.K.
Age-Related Macular
Degeneration E. M. R. Users
Group38
11,135 79.7 63.0 — — — — Retrospective
Zarranz-Ventura et al39 11,135 79.0 63.5 — — — — —
Muniraju et al40 156 82.7 66.0 — — — — Retrospective
Pushpoth et al15 1,017* 75.0 — 28.6 59.76 11.69 Retrospective
Rotsos et al41 50 80.0 60.0 10.0 — 90.0 — Retrospective
North America
Rayess et al42 196† 80.3 65.1 — — — — Retrospective, interventional,
consecutive case series
Rofagha et al43 155 — — 31.0 25.0 45.0 — Cross-sectional cohort study
Bellerive et al44 45 76.9 71.0 38.0 34.0 18.0 2.0 Retrospective
Katz et al16 56 — — — — — — Retrospective
Monthly 28* 80.8 Not
reported
19.0 — 77.0 3.0
PRN 28* 78.5 Not
reported
10.0 — 90.0 0
Bandukwala et al45 94 81.0 63.0 16.0 16.0 26.0 — Retrospective
Engelbert et al46 16† 79.0 75.0 — — — 16 Retrospective
Gupta et al20 92* 80.6 66.3 19.6 28.7 52.2 — Retrospective
Dadgostar et al47 124* 81.3 64.5 16.3 16.3 66.3 — Retrospective
Australia
Barthelmes et al48 655 79.4 61.4 16.8 17.3 46.0 6.0 Retrospective
Gillies et al49 1,007*,† 79.5 65.8 16.4 15.5 55.8 4.0 Database observational study
Abedi et al17 120† 77.7 59.2 27.5 — 72.5 — Prospective cohort study
Arnold et al50 1,011 79.4 61.3 15.9 18.1 50.1 4.3 Database observational study
Barthelmes et al51 176 78.6 62.0 — — — — Retrospective
Gillies et al52 646* 79.2 61.9 — 30.5 69.5 — Database observational study
Gillies et al53 850*† 79.3 61.3 48.4 21.4 53.6 7.7 Prospective
Toalster et al54 45 81.7 64.0 — 24.4 44.4 — Prospective
Michalova et al18 158* 80 73.4 23.0 17.0 60.0 — Retrospective
*Completely or mostly treatment naive.
†Includes some patients who received bevacizumab.
PC, predominantly classic.
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Table 2. Visual Acuity and Treatment Regimen Data in the Included Studies
Article
Change in VA (ETDRS Letters)
Mean No.
Injections Mean No. Visits Treatment Regimen
Baseline Nearest
Snellen Score
Written Within Brackets 1 yr 2 yr $3 yr
International
Holz et al13 55.4 (6/24) +2.4 +0.6 — 3.6 6.8 Not reported
Germany 52.9 (6/30) +1.1 20.8 — 2.8 5.4 (PRN)
France 56.0 (6/24) +0.8 21.1 — 3.2 6.7 (PRN)
United Kingdom 55.0 (6/24) +6.0 +4.1 — 4.5 9.2 (PRN)
Italy 65.5 (6/15) 0.0 22.9 — 2.6 3.3
Netherlands 50.1 (6/30) +3.8 +2.6 — 4.3 6.4
Canada 47.2 (6/38) +3.2 +1.6 — 5.0 6.9
Ireland 64.7 (6/15) +2.3 +3.3 — 5.5 6.8
Venezuela 48.3 (6/30) +2.6 +1.4 — 1.6 4.2
Silva et al21 60.7 (6/19) — 24.3 — 3.1 Not reported PRN
Continental Europe
Souied et al22 56.8 (6/24) +4.3 — — 5.6 7.4 Loading and PRN (4.1%) PRN
(6.5%) monthly (0.1%)
van Asten et al23 45.1 (6/38) +5.6 +3.4 — 6.7 Not reported Loading and PRN
Frennesson and Nilsson24 58.4 (6/19) +1.8 +1.0 +0.1 3.4 10.6 Loading and PRN
Mantel et al25 58.3 (6/19) +9.8 — — 7.8 4.0 Loading and PRN
Menghini et al26 55.2 (6/24) +5.0 +1.5 — 4.5 9.7 Loading and PRN (28.4%)
PRN
Wolf and Kampik27 75.0* (6/9.5) +0.4* — — 4.5 Not reported Loading and PRN
Cohen et al28 53.2 (6/24) +3.2 — — 5.1 8.6 Loading and PRN
Falk et al39 53.2 (6/24) — 50.5 — 4.4 Not reported Loading and PRN
Finger et al30 49* (6/30) 21.0* — — 4.3 Not reported Loading and PRN
Holz et al31 — — — — — — —
Germany 48.8 (6/30) 20.8 — — 4.0 Not reported Loading and PRN
Netherlands 45.1 (6/38) +5.6 — — 5.1 Not reported —
Belgium 56.3 (6/24) +2.5 — — 5.0 Not reported —
Sweden 58.3 (6/19) +1.0 — — 4.4 Not reported —
Rakic et al32 56.3 (6/24) +1.6 22.4 — 3.8 Not reported Loading and PRN
Biarnés et al33 57.8 (6/19) +1.3 — — 3.5 Not reported PRN
Heimes et al14 54.5* (6/24) 21.0* — — 4.98 Not reported Loading and PRN
Hjelmqvist et al19 58.3 (6/19) +1.0 — — 4.7 10.3 Loading and PRN
Oubraham et al34 — — — — — — —
PRN 59.4 (6/19) +2.3 — — 5.2 8.8 PRN
Treat and extend 61.2 (6/19) +10.8 — — 7.8 8.5 Treat and extend
Querques et al35 46* (6/38) +9.0 +7.0 — — Not reported Loading and PRN
Cohen et al36 56.15 (6/24) +0.7 — — 3.79 8.07 Loading and PRN
Rothenbuehler et al37 49.7 (6/30) +7.3 +6.3 — 5.0 Not reported PRN
United Kingdom
(continued on next page)
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Table 2. (Continued )
Article
Change in VA (ETDRS Letters)
Mean No.
Injections Mean No. Visits Treatment Regimen
Baseline Nearest
Snellen Score
Written Within Brackets 1 yr 2 yr $3 yr
Writing Committee for the U.K. Age-
Related Macular Degeneration E. M.
R. Users Group38
55 (6/24) +2 +1 22 4.3 8.5 Loading and PRN
Zarranz-Ventura et al39 — — — — — — Loading and PRN
First eye 52* (6/30) — 0* +0.5* 4.4 8.1
Second eye 64.5* (6/15) — 23.5* 27.5* 4.3 9.1
Muniraju et al40 48.2 (6/30) +3.0 +2.2 +0.9 3.4 Not reported Loading and PRN
Pushpoth et al15 — — — — 3.74 Not reported Treat and extend
Pretreatment 50.43 (6/30) +2.7 +0.9 20.42
No pretreatment 54.09 (6/24) +3.8 +2.4 +0.23
Rotsos et al41 46 (6/38) +4.6 — — 4.7 11 Loading and PRN
North America
Rayess et al42 43* (20/136) +11.6 +10.7* +13.6* 6.4 6.4 Treat and extend
Rofagha et al43 54.3 (6/24) — — 26.9 2.0 — Monthly and PRN
Bellerive et al44 50.5* (6/30) +7.0* — — 4.92 — Loading and PRN
Katz et al16 — — — — — — —
Monthly 37.5* (6/60) +13 — — 12 13 Monthly
PRN 36.5* (6/60) +10 — — 8 11 Loading and PRN
Bandukwala et al45 52.5 (6/24) +2.9 — — 5.1 9.4 —
Engelbert et al46 58* (6/19) — +1* +1* 10 10 Treat and extend
Gupta et al20 43* (6/38) +13* +11* — 7.45 7.93 Treat and extend
Dadgostar et al47 49* (6/30) +2.0* — — 5.2 — PRN
Australia
Barthelmes et al48 — — — — — — Treat and extend and PRN (20%)
Low 55.8 (6/24) +6.8 — — 7.6 —
Moderate 53.7 (6/24) +8.3 — — 7.9 —
High 54.0 (6/24) +6.2 — — 8.4 —
Persistent 54.0 (6/24) +5.5 — — 8.3 —
Gillies et al49 55.3 (6/24) +5.5 — — 4.2 Not reported —
Abedi et al17 51.2 (6/30) +9.5 +8.0 — 7.1 7.1 Loading and Treat and extend
Arnold et al50 56.5 (6/24) — +5.3 — 6.5 7.4 Treat and extend
Barthelmes et al51 — — — — — — —
First eye 49.7 (6/30) +7.2 — — 6.3 Not reported —
Second eye 61.2 (6/19) +3.8 — — 7.3 Not reported —
Gillies et al52 55 (6/24) +4.9 — — 7.3 9.5 Treat and extend (74%) PRN and
monthly (22%) Monthly (4%)
Gillies et al53 57.1 (6/24) +4.7 — — 7.0 — —
Toalster et al54 61.0* (6/19) +6.0* — — 8.0 7.0 Loading and Treat and extend
Michalova et al18 62.0* (6/19) +7.0* — — 9.2 — —
*Converted to ETDRS letters.
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CI: 25.3 to 7.5) ETDRS letters at 1 year (n = 24,039),
2 years (n = 17,928), and $3 years (n = 13,012),
respectively. There was a regional difference in VA
change at 1 year, with a gain of +3.1 (95% CI: 1.2 to
5.0), +2.5 (95% CI: 1.3 to 3.8), +6.0 (95% CI: 3.2 to
8.7), and +7.7 (95% CI: 3.0 to 12.4) ETDRS letters in
continental Europe (n = 9,988), United Kingdom (n =
12,886), North America (n = 795), and Australia (n =
323), respectively.
Data were extracted for treat-and-extend and PRN
regimens where it was speciﬁed, as shown in Table 2.
For studies based purely on PRN regimens (n =
21,612), the mean VA change was +3.5 (95% CI:
2.0 to 5.0), +1.3 (95% CI: 21.6 to 4.2), and 21.9
(95% CI: 29.8 to 6.0) ETDRS letters at 1 year
(n = 20,247), 2 years (n = 14,408), and $3 years
(n = 11,714), respectively. In contrast, patients of stud-
ies based solely on treat-and-extend regimens (n =
2,566) had a mean VA change of +8.8 (95% CI: 5.8
to 11.8), +6.7 (95% CI: 3.2 to 10.1), and +5.4 (95%
CI: 24.1 to 14.9) ETDRS letters at 1 year (n = 1,539),
2 years (n = 2,521), and $3 years (n = 1,298) respec-
tively. Patients receiving a treat-and-extend regimen
achieved signiﬁcantly better outcomes at 1 and 2 years
(P , 0.001 and P = 0.021 respectively; mixed-effects
models) compared with patients on PRN. This differ-
ence was not signiﬁcant at $3 years (P = 0.168;
mixed-effects models).
Most patients had a baseline VA between 35 and 55
ETDRS letters (n = 17,464; 6/60 to 6/24 Snellen
Table 3. Ocular and Systemic Safety Outcomes of Each Included Study
Article
Total No. Adverse
Events
Ocular
(Endophthalmitis) Systemic (CVA, ACS) Deaths
International
Holz et al13 5* 4* Not reported 1*†
Silva et al21 359 2 1 5†
Continental Europe
van Asten et al23 64‡ Not reported 3 18
Frennesson and
Nilsson24
65 Not reported 3 26
Mantel et al25 0 0 0 0
Wolf and Kampik6 37 Unable to be
calculated
Unable to be
calculated
Unable to be calculated
Finger et al27 505 51§ 6§ 42†
Holz et al31 128 5 29 Not reported
Germany 84 4 23 Not reported
the Netherlands 22 0 2 Not reported
Belgium 18 1 2 Not reported
Sweden 4 0 2 Not reported
Rakic et al32 155 13 6 5
Hjelmqvist et al19 16 0 3 4
Querques et al35 0 0 0 0
Rothenbuehler
et al37
0 0 0 0
United Kingdom
Rotsos et al41 0 0 0 0
North America
Bellerive et al44 Unable to be
calculated
0 0 0
Engelbert et al46 0 0 0 0
Gupta et al20 0 0 0 0
Australia
Barthelmes et al48 9 4 Not reported Not reported
Abedi et al17 9 4 2 4
Arnold et al50 35 2 Not reported Not reported
Gillies et al53 82 2 Not reported Not reported
Toalster et al54 0 0 0 0
Michalova et al18 10 0 6 0
*Value had to be calculated.
†Deaths separate to reported adverse events.
‡Adverse events not related to the ranibizumab treatment.
§Adverse events related to the ranibizumab treatment.
ACS, acute coronary syndrome; CVA, cerebrovascular accident.
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Table 4. Weighted Outcome Means and Overall Outcome Measures as Estimated by Random-Effects Models, and
Regional and Treatment Regimen Outcome Measures as Estimated by Mixed-Effects Models
Variable Weighted Mean
Random-Effects
Estimate (95% CI) I2 (%)
Moderator R2 (%)
Region Regimen
Baseline age
Overall 78.6 78.8 (78.0 to 79.5) 96.5 25.1 0.0
PRN 78.3 78.5 (77.6 to 79.4)
T&E 77.7 79.0 (77.4 to 80.6)
Baseline VA
Overall 55.3 53.6 (51.0 to 56.2) 98.9 22.5 0.0
Europe 56.5 56.0 (53.3 to 58.7)
United Kingdom 54.8 53.6 (50.6 to 56.7)
United States 47.4 46.6 (43.5 to 49.7)
Australia 57.8 57.5 (51.2 to 63.9)
PRN 55.4 53.0 (50.0 to 56.0)
T&E 53.5 52.0 (46.5 to 57.6)
DVA 1 year
Overall +2.1 +5.0 (3.4 to 6.6) 97.9 0.0 34.1
Europe +1.2 +3.1 (1.2 to 5.0)
United Kingdom +2.3 +2.5 (1.3 to 3.8)
North America +7.0 +6.0 (3.2 to 8.7)
Australia +7.8 +7.7 (3.0 to 12.4)
PRN +1.7 +3.5 (2.0 to 5.0)
T&E +5.7 +8.8 (5.8 to 11.8)
DVA 2 year
Overall +1.3 +3.4 (0.9 to 5.8) 97.7 13.3 30.4
PRN +0.8 +1.3 (21.6 to 4.2)
T&E +4.7 +6.7 (3.2 to 10.1)
DVA $3 years
Overall 21.6 +1.1 (25.3 to 7.5) 98.5 0.0 26.0
PRN 22.0 21.9 (29.8 to 6.0)
T&E +2.2 +5.4 (24.1 to 14.9)
Mean yearly injections
Overall 4.4 5.4 (4.6 to 6.2) 99.8 24.5 31.5
Europe 4.3 4.3 (3.5 to 5.1)
United Kingdom 5.0 5.6 (4.8 to 6.4)
North America 6.2 6.1 (5.3 to 6.9)
Australia 7.8 7.7 (5.9 to 9.5)
PRN 4.3 4.7 (4.0 to 5.5)
T&E 5.2 6.9 (5.6 to 8.2)
Mean injections year 1
Overall 5.0 6.3 (5.2 to 7.5) 99.7 — 44.1
PRN 5.2 5.4 (4.1 to 6.8)
T&E 6.6 7.3 (5.9 to 8.6)
Mean injections year 2
Overall 3.8 4.4 (3.2 to 5.6) 99.3 — 15.8
PRN 3.4 3.7 (1.8 to 5.5)
T&E 4.5 4.9 (3.3 to 6.5)
Mean injections year 3
Overall 3.8 3.3 (1.1 to 5.6) 99.5 — 0.0
PRN 3.6 2.8 (0.0 to 6.8)
T&E 3.2 4.0 (0.0 to 8.9)
Mean number of visits
Overall 7.8 8.3 (7.2 to 9.4) 99.8 0.0 5.7
PRN 7.8 8.8 (7.4 to 10.3)
T&E 7.3 7.6 (5.9 to 9.3)
Mean visits year 1
Overall 9.0 8.4 (7.1 to 9.7) 99.8 — 4.1
PRN 9.0 8.6 (6.8 to 10.3)
T&E 7.6 7.8 (5.5 to 10.1)
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equivalent). This was followed by the 55 to 70 ETDRS
letters group (n = 4,675; 6/24 to 6/12 Snellen equiva-
lent) and those with VA .70 ETDRS letters
(n = 1,729; .6/12 Snellen equivalent). Patients who
commenced treatment with better baseline VA main-
tained better VA up to at least 36 months (Figure 1).
The mean change in VA in the ﬁrst year of treatment
generally increased with the mean number of injec-
tions that were administered that year (Figure 2).
Treatment Burden
The patients collectively received a mean number
of 5.4 injections (95% CI: 4.6 to 6.2) and 8.3 visits
(95% CI: 7.1 to 9.7) per year. There were more
injections and visits in the ﬁrst year—with patients
receiving a mean of 6.3 injections (n = 25,024; 95%
CI: 5.2 to 7.5) and 8.4 visits (n = 15,559; 95% CI:
7.1 to 9.7). In the second year, there were 4.4 injec-
tions (n = 17,704; 95% CI: 3.2 to 5.6) and 7.7 visits
(n = 13,980; 95% CI: 5.5 to 9.8). For subsequent
years, there was an annual mean of 3.3 injections
(n = 13,104; 95% CI: 1.1 to 5.6) and 7.3 visits
(n = 11,707; 95% CI: 4.9 to 9.8).
There was a regional difference in the number of
injections that were administered per year. The mean
injections administered per year was 4.3 (95% CI: 3.5
to 5.1), 5.6 (95% CI: 4.8 to 6.4), 6.1 (95% CI: 5.3 to
6.9), and 7.7 (95% CI: 5.9 to 9.5) in continental
Europe (n = 10,748), United Kingdom (n = 12,886),
North America (n = 703), and Australia (n = 1,334)
respectively.
Patients receiving the PRN regimen received a mean
of 4.7 injections (95% CI: 4.0 to 5.5) and 8.8 (95% CI:
7.4 to 10.3) visits per year, with 5.4 (95% CI: 4.1 to
6.8) injections given in the ﬁrst year (n = 20,313), 3.7
(95% CI: 1.8 to 5.5) injections in the second year (n =
14,184), and 2.8 (95% CI: 0.0 to 6.8) injections in the
third year (n = 11,714). These patients had 8.6 (95%
CI: 6.8 to 10.3) visits in the ﬁrst year (n = 14,171), 9.2
(95% CI: 4.4 to 14.0) visits in the second year (n =
12,557), and 8.2 (95% CI: 0.0 to 17.5) visits on aver-
age per year in subsequent years (n = 11,403).
Patients on the treat-and-extend regimen received
signiﬁcantly more injections (6.9; 95% CI: 5.6 to 8.2)
and had fewer visits (7.6; 95% CI: 5.9 to 9.3) per year
compared with patients on PRN (P , 0.001 and P ,
Table 4. (Continued )
Variable Weighted Mean
Random-Effects
Estimate (95% CI) I2 (%)
Moderator R2 (%)
Region Regimen
Mean visits year 2
Overall 7.7 7.7 (5.5 to 9.8) 99.8 — 3.2
PRN 7.9 9.2 (4.4 to 14.0)
T&E 6.5 7.6 (4.6 to 10.7)
Mean visits year 3
Overall 8.2 7.3 (4.9 to 9.8) 96.6 — 2.3
PRN 8.3 8.2 (0.0 to 17.5)
T&E 6.4 7.0 (1.2 to 12.8)
Amount of heterogeneity between studies is given by I2 and the amount that is explained by moderators study region and treatment
regimen in mixed-effects models is given R2 where applicable.
Fig. 1. Mean VA at baseline and year 1, 2, and 3 or more in 3 initial
VA groups.
Fig. 2. Mean change in VA versus the mean number of injections
administered, in the ﬁrst year of treatment of included studies.
REAL-WORLD OUTCOMES IN NAMD  KIM ET AL 1427
0.001, respectively; mixed-effects models). These pa-
tients received 7.3 (95% CI: 5.9to 8.6) injections in the
ﬁrst year (n = 2,458), 4.9 (95% CI: 3.3 to 6.5) injec-
tions in the second year (n = 2,521), and 4.0 (95% CI:
0.0 to 8.9) injections in the third year (n = 1,390).
They also visited their ophthalmologist 7.8 (95% CI:
5.5 to 10.1) times in the ﬁrst year (n = 361), then 7.6
(95% CI: 4.6 to 10.7) times in the second year (n =
424), and 7.0 (95% CI: 1.2 to 12.8) times on average
per year in the subsequent years (n = 304).
There was a signiﬁcant reduction in injections from
years 1 and 2 for treat-and-extend and PRN (P = 0.011
and P = 0.046, respectively; metaregression on mean
differences) but not between years 2 and 3 (P = 0.667
and P = 0.514, respectively). There was no signiﬁcant
change in the number of visits from year to year for
both treat-and-extend and PRN.
Dose of Ranibizumab Used
A few studies used a treatment dosage that differed
from the standard 0.5 mg of ranibizumab. Michalova
et al18 used 0.3-mg ranibizumab until April 2007 when
the dosage was changed to 0.5 mg, whereas Hjelmqv-
ist et al19 used 0.23 mg ranibizumab in their study.
Data from Hjelmqvist et al19 were removed from our
analysis as it was based solely on a nonstandard dose.
Also, Gupta et al20 did not comment on the dose that
they administered and it was therefore assumed that
they used a dose of 0.5 mg, which is licensed in the
United States for nAMD where the study is based.
Safety Outcomes
There were 648 adverse events reported in total,
with 17 cases of endophthalmitis, 41 patients devel-
oping cerebrovascular accident and acute coronary
syndrome, and 36 deaths. Many of the included
observational studies did not include sufﬁcient data
on safety outcomes (Table 3).
Heterogeneity
The amount of heterogeneity (I2) in each of the out-
come measures was .95%. The R2 value for region
was 25% for baseline age, baseline VA, and mean
injections received per year. The R2 value for regimen
was 30% for VA change.
Discussion
This metaanalysis of real-world observational stud-
ies of intravitreal ranibizumab therapy for nAMD
demonstrates successful prevention of severe visual
loss. The degree of improvement in VA was greatest in
the ﬁrst year of treatment; however, the initial gain
was not always maintained, with a gradual decline
observed in the second and subsequent years. Patients
receiving a treat-and-extend regimen also had better
VA outcomes with more injections and fewer visits
than those receiving PRN treatment.
There was an association between observed VA
outcomes and injection frequency, which was also
reﬂected in the regional variation in the initial gain in
VA and maintenance of this improvement over time.
In the ﬁrst year of treatment, the mean number of
intravitreal ranibizumab injections reported in studies
from continental Europe (4.3), United Kingdom (5.6),
North America (6.1), and Australia (7.7), correlated
with the mean gain in VA, +3.1, +2.5, +6.0 and +7.8
ETDRS letters, respectively. A greater gain in VA in
the ﬁrst year of treatment was therefore generally
observed in regions that administered more intravitreal
ranibizumab injections. There was also less loss of
vision from the second year onwards in patients
receiving a greater number of injections. This associ-
ation may therefore suggest that the frequency of in-
jections could be an important independent indicator
of improvement in VA outcomes.
Alternatively, it is possible that the observed results
may be caused by underlying differences in the
populations rather than the frequency of injections
administered, considering that the baseline VA of
these regions ranged from 47.4 to 57.8 ETDRS letters
(6/38 to 6/19 Snellen equivalents).
The amount of heterogeneity in each of the outcome
measures was substantial (I2 . 95%). For baseline
age, baseline VA, and mean injections received per
year, 25% of this heterogeneity can be attributed to
the study region. A third of the heterogeneity in VA
change between studies can be explained by the treat-
ment regimen (33.8% of the heterogeneity for the ﬁrst
year and 30.9% for the second). Study region explains
much less for this outcome. However, the pseudo R2
statistic can be very imprecise particularly if the num-
ber of studies is small (or the number of studies per
grouping variable is small).55
There was a large variation in VA outcomes across
countries. Having said this, the confounding effect of
restrictions on intravitreal therapy put in place by the
local healthcare systems must be taken into account.
For instance, PRN was used in the United Kingdom,
whereas treat-and-extend was used in Australia. The
local healthcare system is therefore important to
consider when interpreting VA outcomes.
The mean baseline VA was strongly correlated with
long-term visual outcome. Therefore, it is important to
have systems in place to identify nAMD and com-
mence treatment early. Patients are more likely to
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retain vision sufﬁcient for maintaining a driving license
and high level of independence with early treatment.
Restrictions on therapy for patients with nAMD with VA
better than 20/30, as mandated by organizations such as
National Institute for Health and Care Excellence in the
United Kingdom, may adversely affect a group that is
most likely to beneﬁt from treatment.56
This metaanalysis also provides insight into what is
achievable in real-life clinical practice when compared
with Phase 3 studies. The whole cohort of patients in
this metaanalysis gained a mean 5.0 ETDRS letters after
12 months of ranibizumab therapy with a mean number
of 5.4 injections and 8.3 visits per year. In contrast, the
mean gain in VA after 12 months of 0.5 mg ranibizu-
mab therapy was 7.2 ETDRS letters in the MARINA
trial and 11.3 ETDRS letters in the ANCHOR trial,
based on 12 injections and 12 follow-up examinations
over the course of a year. Hence, comparing our
metaanalysis with Phase 3 clinical trials shows that,
on the whole, patients receive fewer injections and visits
in real-world practice and obtain a lower initial gain in
VA after 12 months of intravitreal ranibizumab therapy.
The proportion of arterial thromboembolic events or
death in this metaanalysis were 0.6% (n = 41) and
0.7% (n = 36), respectively. These numbers were gen-
erally lower than in Phase 3 clinical trials, with the
ANCHOR trial reporting proportions of 2.7% and
1.4%, respectively, whilst in the MARINA trial these
proportions were 3.8% and 2.6%, respectively. None-
theless, it is likely that the lower numbers reported in
real-world observational studies represent incomplete
capture of systemic safety data.
The multicenter and observational nature of the
included studies was both a strength and limitation in
this metaanalysis. The large pooled population of
patients from multiple centers and countries provided
data that served as a real-life standard to which local
outcomes can be compared. These observational
studies also provide valuable information on how the
results from Phase 3 clinical trials may translate to the
wider population in which the stringent inclusion and
exclusion criteria of the clinical trials no longer apply.
However, they are also a few limitations as clinical
protocols such as dosing may change over time and
the data depend on the documentation protocols and
management criteria followed by each center, which
may have varied. The rate of patients who had an
arterial thromboembolic event or death per year could
not be calculated because of the variation in the
collection of safety data across studies. The VA was
also measured in a standard clinical setting rather than
the more accurate but time-consuming best-corrected
VA measurements performed in a clinical trial setting.
It is also possible that the baseline characteristics of
study populations of different included studies were not
similar. For instance, nAMD is being identiﬁed and
treated earlier in its disease course as anti-vascular
endothelial growth factor treatment becomes more
widespread. More recent studies are therefore more
likely to include eyes that are healthier than older
studies, which has implications for the results obtained.
This metaanalysis has also highlighted the need for
a standardized framework to collect outcome data of
efﬁcacy and safety of intravitreal ranibizumab for
nAMD. For instance, the International Consortium for
Health Outcomes Measurements (ICHOM) has
a global standard set of outcome measures for macular
degeneration based on consensus of international
experts.57 A standardized framework would facilitate
a more consistent and accurate collection of clinically
meaningful data and make it easier to compare out-
comes. The collection of large amounts of data on the
treatment of nAMD in routine practice can also be
achieved using programs such as Medisoft or web-
based tools developed in the Fight Retinal Blindness!
Project, which helps to consolidate records from mul-
tiple sites and ophthalmic instruments.58 Addressing
this issue will allow us to evaluate new treatments as
they are introduced into real-world practice in a more
timely manner than large prospective Phase 4 studies.
In conclusion, patients who received intravitreal
ranibizumab therapy in real-world clinical practice for
nAMD were, in general, protected against severe vision
loss. However, the included observational studies did
not report the same magnitude of VA improvement as
Phase 3 clinical trials and these VA improvements were
not maintained in the long term, particularly with
treatment regimens that had low injection frequency.
More research is warranted using standardized data
collection methods to allow easier comparison of
efﬁcacy and safety outcomes to improve standards
globally.
Key words: age-related macular degeneration, neo-
vascular, observational, ranibizumab, real-world out-
comes.
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